MetLife Investment Management’s Viemed Healthcare VMD Stock Holding History

MetLife Investment Management’s Portfolio VMD Stock Details VMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Sell	18,170 -1,063	-6%	-$10.5K	﹤0.01%	2401
2026 Q1	$177K	Buy	19,233 +668	+4%	+$5.56K	﹤0.01%	2291
2025 Q4	$138K	Buy	18,565 +6,408	+53%	+$43.9K	﹤0.01%	2457
2025 Q3	$82.5K	Sell	12,157 -7,466	-38%	-$50.5K	﹤0.01%	2726
2025 Q2	$136K	Hold	19,623	–	–	﹤0.01%	2385
2025 Q1	$143K	Sell	19,623 -337	-2%	-$2.65K	﹤0.01%	2370
2024 Q4	$160K	Hold	19,960	–	–	﹤0.01%	2412
2024 Q3	$146K	Hold	19,960	–	–	﹤0.01%	2449
2024 Q2	$131K	Buy	19,960 +1,859	+10%	+$14K	﹤0.01%	2473
2024 Q1	$171K	Hold	18,101	–	–	﹤0.01%	2281
2023 Q4	$142K	Hold	18,101	–	–	﹤0.01%	2420
2023 Q3	$122K	Hold	18,101	–	–	﹤0.01%	2477
2023 Q2	$177K	Buy	+18,101	New	+$184K	﹤0.01%	2353
2021 Q2	–	Sell	-2,616	Closed	-$26.5K	–	2491
2021 Q1	$26.5K	Sell	2,616 -14,073	-84%	-$132K	﹤0.01%	2300
2020 Q4	$130K	Sell	16,689 -1,201	-7%	-$10.6K	﹤0.01%	2185
2020 Q3	$155K	Hold	17,890	–	–	﹤0.01%	2013
2020 Q2	$172K	Buy	+17,890	New	+$139K	﹤0.01%	1993

Other funds holding VMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Forager Capital Management Birmingham, Alabama $266M AUM 40% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

MetLife Investment Management's VMD Position: Q2 2026 in Review

MetLife Investment Management reduced its Viemed Healthcare (VMD) stake by 5.5% in Q2 2026, selling an estimated $10.5K and leaving 18,170 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

MetLife Investment Management first reported a position in VMD in Q2 2020 and has held it in 17 quarters since. 166 funds tracked by Wall St. Rank hold VMD as of Q2 2026.

MetLife Investment Management held 18,170 shares of Viemed Healthcare worth $207K as of Q2 2026.
MetLife Investment Management sold 1,063 Viemed Healthcare shares in Q2 2026, an estimated $10.5K.
Viemed Healthcare made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2401 holding.
MetLife Investment Management first reported a position in Viemed Healthcare in Q2 2020 and has held it in 17 quarters since.
166 funds tracked by Wall St. Rank held Viemed Healthcare as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.